SCHEMBL7032379

SCHEMBL7032379

COc1cccc([C@H]2CC(=O)c3ccccc3O2)c1OC

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 5/20 0.74
KDM4E B2RXH2 5/20 0.59
LMNA P02545 1/20 0.59
ADORA3 P0DMS8 2/20 0.58
AR P10275 2/20 0.58
HSD11B1 P28845 1/20 0.58
AKR1C3 P42330 1/20 0.58
MAOB P27338 4/20 0.57
MAPT P10636 2/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
HSD17B10 Q99714 4/20 0.56
ALDH1A1 P00352 3/20 0.56
HPGD P15428 1/20 0.56
AXL P30530 1/20 0.54
GAA P10253 1/20 0.51
ALOX15 P16050 1/20 0.51
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51
TDP1 Q9NUW8 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7032375 1.00 CYP19A1 (0.74) CYP19A1KDM4ELMNAADORA3AR
SCHEMBL8093207 0.89 CYP19A1 (0.74) CYP19A1KDM4EADORA3ARHSD11B1
SCHEMBL8093202 0.89 CYP19A1 (0.74) CYP19A1KDM4EADORA3ARHSD11B1
SCHEMBL15951305 0.86 CYP19A1 (0.60) CYP19A1KDM4EADORA3ARHSD11B1
SCHEMBL7024724 0.85 CYP19A1 (0.83) CYP19A1KDM4EARMAOBMAPT
SCHEMBL17318031 0.85 CYP19A1 (1.00) CYP19A1KDM4EMAOBMAPTHSD17B10
SCHEMBL7024730 0.85 CYP19A1 (1.00) CYP19A1KDM4EMAOBMAPTHSD17B10
SCHEMBL26679501 0.78 CYP19A1 (0.72) CYP19A1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL15619210 0.78 CYP19A1 (0.59) CYP19A1KDM4EADORA3ARHSD11B1
SCHEMBL15619353 0.78 CYP19A1 (0.59) CYP19A1KDM4EADORA3ARHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003057210-A1 COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID KIMBERLY-CLARK WORLDWIDE, INC. (US) 2003-07-17 WO disclosed
US-20030125264-A1 Methods For Treating Wounds KIMBERLY-CLARK WORLDWIDE, INC. 2003-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125264-A1 Methods For Treating Wounds FGF2, MMP1, FIBP CYP19A1 460/4885KDM4E 2309/4885LMNA 1288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.